Peptide Therapeutics Market: Industry Analysis and Outlook, 2030

The global peptide therapeutics market size was valued at USD 39.3 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 6.4% from 2022 to 2030.

The global Peptide Therapeutics Market size is expected to reach USD 68.7 billion by 2030, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 6.4% from 2022 to 2030. Increasing demand for efficient and rapid-acting therapeutics for the treatment of cancer and other lifestyle-associated disorders, which result in lesser adverse effects, is anticipated to propel market growth. The rising incidence of cancer calls for exploring and introducing other means of therapies and low-cost treatment alternatives is expected to drive the market. Moreover, the growing geriatric population is expected to widen the consumer base by triggering the incidence rate of target diseases such as cancer and diabetes, which is expected to drive the demand for peptide therapeutics.

As per the International Agency for Research on Cancer (GLOBOCAN 2020) report, there will be 19,292,789 new cancer cases diagnosed globally in 2020, with 9,958,133 cancer deaths. Furthermore, the five-year prevalence of cancer was projected to be 50,550,287 worldwide. The global number of new cases of cancer is projected to reach 28,887,940 by 2040. As a result, the higher incidence of cancers around the world is set to perform an important role in the development of peptide therapeutics over the forecast period. Besides that, increasing awareness among health care providers and patients about the negative effects of chemotherapy and/or radiation therapy is a primary factor influencing the increased emphasis on alternative therapeutics like peptide-based drugs.

Technological advancements in the peptide manufacturing process are driving the market during the forecast period. Manufacturers and suppliers are focusing on the adoption of novel technologies to manufacture efficient drug molecules with low time and capital investment. Improvement in purification and automation process and less generation of waste are additional factors contributing to the market growth. For instance, in March 2022, Amgen announced the official opening of its latest bio-manufacturing facility in Holly Springs, North Carolina. The facility, which is set to open in 2025, will help cope with the growth of Amgen's medicines, which treat serious diseases like cancer and heart disease.

The COVID-19 pandemic is anticipated to spur the spectrum of cancer care, which includes delayed diagnoses, therapeutic interventions, and the impeding of clinical trials focused on developing cost-effective therapeutics for cancer treatment, with peptide therapeutics for cancer treatment being no exception, as per a research article published in Nature Cancer, 2020. There have been 21 peptide drugs in therapies for the treatment of COVID-19 as of May 2020, such as 15 synthetic peptides for the therapies of acute respiratory distress syndrome (ARDS) as well as other respiratory illnesses induced by severe acute respiratory infection. However, current implementations of peptide therapeutics in oncological and metabolic disorders and other fields have been hampered by drug shortages, operational problems, and the slow progress of clinical trials involving non-COVID-19 therapeutics.

For instance, in May 2022, EVER Pharma announced that Bortezomib has received EU-wide approval for the treatment of individuals with symptomatic myeloma and mantle cell lymphoma1. In May 2022, The European Commission approved Novartis' Jakavi post-steroid therapy for acute and chronic graft-versus-host ailments. Jakavi will be the first JAK1/2 inhibitor widely available for patients in Europe with steroid-refractory graft-versus-host ailment. In September 2021, Nimble Therapeutics and Incyte entered into strategic collaborative research to discover additional new peptide therapies.

Related Press Release@ Peptide Therapeutics Market Report

Peptide Therapeutics Market Report Highlights

• By application, cancer held the second-largest revenue share in 2021 owing to the increasing demand for alternative therapeutics over conventional treatment options. Peptides are being used as potential therapeutic agents in cancer treatment
• The generic type segment is expected to showcase an upward shift due to the patent expiration of blockbuster peptides and supportive government initiatives pertaining to the introduction of the generic class
• By type of manufacturers, the outsourced segment is expected to expand at a lucrative CAGR of 6.6% over the forecast period owing to the requirements of complex procedures and a shift in preference toward outsourcing, which helps in eliminating the cost of production
• By synthesis technology, hybrid technology is expected to witness the fastest growth over the forecast period. Benefits associated with this technology such as time conservation and ease of usage for both solid- and liquid-phase peptide synthesis are the key factors affirming growth
• North America held the largest share in terms of revenue in 2021 owing to a higher level of awareness pertaining to genomics and proteomics products, well-established R&D infrastructure, and rising funding initiatives
• Asia Pacific is expected to register a lucrative growth rate of 8.7% over the forecast period. The presence of an established generic industry and API providers in this region, coupled with the growing economic stability in some of the countries, is expected to propel market growth

Reviews

[Spamalott]

So for fun, I added another review of these crooks. This one on Quora.

For more than a year, this company has regularly invaded the Writers Café website, one of the oldest, non-commercial writing venues on the internet. And they do that in spite of repeated requests to stop. Does an ethical company do that? No.

Ignoring site rules and the desires of the members, they drop spam for their company, falsely listing that spam as a chapter in a pretend book. Does an ethical company lie that way? No. Does a successful company have to resort to such tactics when advertising on the site is available at reasonable cost? Absolutely not.

In fact, the author of the spam is so inept that he can’t handle the HTML formatting that people experienced in presentation on the internet take for granted.

He lacks skill in working with the HTML language used on the Internet, so all the indentations he included were lost—both of sections under a heading, and paragraphing within that section. And he either never noticed, or didn’t take the time to learn how to fix the problem. Either way…

Aside from being dishonest, and inept, posting spam in the area reserved for the stories and poetry of members is a violation of site rules, disrespectful of the members, and, demonstrates that to them, a potential coin in the pocket is more important than ethics.

They’re supposed to be enhancing their reputation and attracting customers with that spam. Instead, they demonstrate a lack of writing skills, because the supposed condensations of the actual report are written in a way that bores the reader in a paragraph or two. That’s dumb because their entire sales pitch is based on how well they write.

In short, while the company expects people to see them as being experts in their field, they cannot handle a page of promotion for what they sell. You can see the inept formatting of today’s spam here:

https://www.writerscafe.org/writing/Industryinsights/2829563/

[Spamalot]

Ahh, the lowest of the low Indian data w****s is spamming for their poorly written crap on a site where no one ever buys one. So add stupid to poor writing.